These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30835045)

  • 1. Impact of Myeloid Reservoirs in HIV Cure Trials.
    Mitchell BI; Laws EI; Ndhlovu LC
    Curr HIV/AIDS Rep; 2019 Apr; 16(2):129-140. PubMed ID: 30835045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies.
    Delannoy A; Poirier M; Bell B
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30889861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
    Chun TW; Fauci AS
    AIDS; 2012 Jun; 26(10):1261-8. PubMed ID: 22472858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for measuring HIV reservoir size in cure-directed clinical trials.
    Abdel-Mohsen M; Richman D; Siliciano RF; Nussenzweig MC; Howell BJ; Martinez-Picado J; Chomont N; Bar KJ; Yu XG; Lichterfeld M; Alcami J; Hazuda D; Bushman F; Siliciano JD; Betts MR; Spivak AM; Planelles V; Hahn BH; Smith DM; Ho YC; Buzon MJ; Gaebler C; Paiardini M; Li Q; Estes JD; Hope TJ; Kostman J; Mounzer K; Caskey M; Fox L; Frank I; Riley JL; Tebas P; Montaner LJ;
    Nat Med; 2020 Sep; 26(9):1339-1350. PubMed ID: 32895573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy.
    Cattin A; Wiche Salinas TR; Gosselin A; Planas D; Shacklett B; Cohen EA; Ghali MP; Routy JP; Ancuta P
    AIDS; 2019 Jul; 33(8):1293-1306. PubMed ID: 30870200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.
    Peters RJ; Stevenson M
    J Virol; 2022 Jun; 96(12):e0048422. PubMed ID: 35604217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current approaches to assess HIV-1 persistence.
    Banga R; Procopio FA; Perreau M
    Curr Opin HIV AIDS; 2016 Jul; 11(4):424-31. PubMed ID: 27054279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing.
    Cunyat F; Rainho JN; West B; Swainson L; McCune JM; Stevenson M
    J Virol; 2016 Jul; 90(14):6255-6262. PubMed ID: 27122585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue reservoirs of HIV.
    Wong JK; Yukl SA
    Curr Opin HIV AIDS; 2016 Jul; 11(4):362-70. PubMed ID: 27259045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Persistence in Adipose Tissue Reservoirs.
    Couturier J; Lewis DE
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):60-71. PubMed ID: 29423731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV reservoirs and strategies for eradication.
    Smith MZ; Wightman F; Lewin SR
    Curr HIV/AIDS Rep; 2012 Mar; 9(1):5-15. PubMed ID: 22249405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 reservoir dynamics in CD4+ T cells.
    Bruner KM; Cohn LB
    Curr Opin HIV AIDS; 2019 Mar; 14(2):108-114. PubMed ID: 30531293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.
    Rose R; Nolan DJ; Maidji E; Stoddart CA; Singer EJ; Lamers SL; McGrath MS
    AIDS Res Hum Retroviruses; 2018 Jan; 34(1):3-8. PubMed ID: 28691499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Eradication: Early Trials (and Tribulations).
    Spivak AM; Planelles V
    Trends Mol Med; 2016 Jan; 22(1):10-27. PubMed ID: 26691297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Reservoirs During Suppressive Therapy.
    Barton K; Winckelmann A; Palmer S
    Trends Microbiol; 2016 May; 24(5):345-355. PubMed ID: 26875617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Importance of Tissue Sanctuaries and Cellular Reservoirs of HIV-1.
    Kalada W; Cory TJ
    Curr HIV Res; 2022 Aug; 20(2):102-110. PubMed ID: 34961449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
    Jean MJ; Fiches G; Hayashi T; Zhu J
    AIDS Res Hum Retroviruses; 2019 Jan; 35(1):1-24. PubMed ID: 30351168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.